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performed. Data collected included: tumour type, technique, 
dose, number of fractions, prescription isodose, acute and 
late toxicity (CTCAE v4.0), local control (LC) and progression 
free survival (PFS). 
 
Results: 12 patients were identified: 8 males and 4 females; 
median age 14.5 years [5-20 years]. Cranial SRS was delivered 
to 9 sites in 7 patients, and extracranial SABR was delivered 
to 8 sites in 5 patients. All patients had a Lansky/ Karnofsky 
score ≥70. All SABR and SRS treatments were performed using 
the Cyberknife® platform; 8 treatments prescribed as a 
single fraction (median dose 19 [18-24] Gy), 4 treatments 
were given in 3 fractions (median dose 28.5 [27-42]Gy) and 5 
treatments in 5 fractions (median dose 30 [30-35]Gy). The 
median prescribing isodose was 79% [70-81%]. For 5 patients 
SRS was delivered post surgical resection with no 
macroscopical residual disease at the time of treatment. The 
treatment for 9 (75%) patients was to previously irradiated 
sites. After a median follow up of 14.5 [0.9-36.2] months 9 
pts (75%) were alive, 2 died from disease progression and 1 
died from unclear cause. MRI response assessment was 
performed at a mean time of 6 [3-17] weeks; 1 patient had a 
complete response, 10 had stable disease (83 %); 1 was not 
assessed due to a rapid clinical deterioration. LC was 100 % 
and 85.7% at 1 and 2 years respectively. PFS was 82.5% at 1 
year and 61.9 % at 2 years. 3 reirradiated patients reported 
symptomatic grade 3 radionecrosis, requiring medical 
therapy. 
 
Conclusion: In this cohort, SABR and SRS with Cyberknife® 
have proven feasible in the subset of paediatric & TYA 
patients with recurrent or oligo-metastatic tumours. It 
achieved good local control even in pre-irradiated patients. 
However optimal patient selection for such a treatment 
approach remains as yet to be determined via an 
international consensus. 
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Purpose or Objective: Particle therapy is not available in our 
country yet, however, quite a few patients are sent abroad 
for such therapy. In the largest health trust, covering a 
population of 2.9 million, 25-40 pediatric patients (< 18 
years) are treated with radiotherapy (RT) yearly. We wanted 
to analyze this group of patient with respect to RT technique 
and diagnosis. 
 
Material and Methods: All pediatric patients treated 
between January 2006 and June 2015 were identified and 
included. The treatment techniques were categorized as 
follows: total body irradiation (TBI), whole CNS RT, 
IMRT/VMAT, stereotactic RT (SRT), 3D conformal RT (CRT), 
kV RT and extracorporal irradiation (ExCRT). Additionally, 
the pediatric patients referred for proton RT abroad were 
registered. 
 
Results: 302 pediatric patients were treated with RT in the 
period. The mean age at treatment were 11.3 ± 4.6 years. 69 
patients (25%) had brain tumors, whereas 50 (18%) and 43 
(16%) patients were diagnosed with lymphoma and leukemia, 
respectively.  
The figure gives the distribution of the treatment techniques 
trough the whole period (upper panel), showing that more 
than 50 % of the patients have been treated with CRT. The 
lower panel in the figure shows the distribution in 2006 (left) 
and 2014 (right), indicating that the proportion of patients 
receiving CRT has decreased from 50 to 38 %. However, the 
number of patients only reduced from 18 in 2006 to 15 in 
2014. The number of patients treated with advanced 
techniques (IMRT/VMAT, SRT) did not change significantly. 
On the other hand, 20 % of the patients were referred for 
proton RT abroad in 2014, while no one received such 
treatment in 2006. The number of patients where the whole 
CNS were treated reduced from 8 (25%) in 2006 to 3 (8%) in 
2014.  
In the whole period 31 patients (10%) were treated with TBI 
and the number of patients per year did not changed 
significantly from 2006 to 2014. 
 
 
 
Conclusion: An official agreement was established with 
proton centers abroad in 2013. The reduction in whole CNS 
treatment throughout the period is due to this agreement. 
Except TBI, kV RT and ExCRT, all the other techniques should 
be replaced with proton RT when such treatment becomes 
available. 
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Purpose or Objective: The Norwegian Breast Cancer Group 
provides national guidelines regarding systemic therapy for 
metastatic breast cancer. While our center adheres to these 
recommendations, use of palliative radiotherapy (PRT) for 
bone metastases is less standardized. Despite general 
recommendations for short course PRT for uncomplicated 
metastases, many physicians prefer ≥10 fractions (long 
course, LC). Our aim was to analyze factors associated with 
prescription of ≥10 fractions. 
 
Material and Methods: This retrospective study included 118 
female patients (all received systemic therapy including 
bone-targeting agents in accordance with national 
guidelines). 
 
Results: Median age was 61 years, and median survival 13 
months. Long-course PRT was prescribed in 60% of patients, 
while 21% had PRT with 8 Gy single fraction to at least one 
target. Reirradiation rate was numerically higher after 8 Gy 
(9%, compared to 5% after LC PRT and 6% after 4 Gy x5, not 
significant). Patients with favorable baseline characteristics 
were significantly more likely to receive LC PRT. These 
characteristics included absence of lung metastases and/or 
